(Q29365161)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Alternatives to antibiotics-a pipeline portfolio review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

0 references

0 references

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Kai Hilpert

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Brian V Jones

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Aras Kadioglu

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

John Rex

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

9

Robert E W Hancock

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

19

Sunil Shaunak

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Lloyd Czaplewski

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Richard Bax

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Mike Dawson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Heather Fairhead

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Vincent A Fischetti

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Simon Foster

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Brendan F Gilmore

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

David Harper

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

David Knowles

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Sigríður Ólafsdóttir

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

David Payne

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Steve Projan

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Jared Silverman

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Christopher M Thomas

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Trevor J Trust

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Peter Warn

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Martha Clokie

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

publication date

13 January 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

Lancet Infectious Diseases

5 March 2020

published in

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

239-251

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

Drugs for bad bugs: confronting the challenges of antibacterial discovery

5 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

ESKAPEing the labyrinth of antibacterial discovery.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

High-sensitivity monoclonal antibodies specific for homoserine lactones protect mice from lethal Pseudomonas aeruginosa infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Identification of anti-virulence compounds that disrupt quorum-sensing regulated acute and persistent pathogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

The anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenem

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

A multifunctional bispecific antibody protects against Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Bactericidal monoclonal antibodies specific to the lipopolysaccharide O antigen from multidrug-resistant Escherichia coli clone ST131-O25b:H4 elicit protection in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Modulation of Intestinal TLR4-Inflammatory Signaling Pathways by Probiotic Microorganisms: Lessons Learned from Lactobacillus jensenii TL2937

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Probiotics for infectious diseases: more drugs, less dietary supplementation.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Probiotics for preventing ventilator-associated pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Engineered bacteriophage lysins as novel anti-infectives

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Engineered endolysin-based "Artilysins" to combat multidrug-resistant gram-negative pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Antibacterial activity of Acinetobacter baumannii phage ϕAB2 endolysin (LysAB2) against both gram-positive and gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Lysins: the arrival of pathogen-directed anti-infectives

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Novel phage lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Phage treatment of human infections.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Effects of antagonistic coevolution on parasite-mediated host coexistence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa ; a preliminary report of efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

SASP gene delivery: a novel antibacterial approach

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Dispersing biofilms with engineered enzymatic bacteriophage

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Modulating immunity as a therapy for bacterial infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Ciprofloxacin Affects Host Cells by Suppressing Expression of the Endogenous Antimicrobial Peptides Cathelicidins and Beta-Defensin-3 in Colon Epithelia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Vitamin D3 supplementation in patients with frequent respiratory tract infections: a randomised and double-blind intervention study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Phenylbutyrate induces cathelicidin expression via the vitamin D receptor: Linkage to inflammatory and growth factor cytokines pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Oral intake of phenylbutyrate with or without vitamin D3 upregulates the cathelicidin LL-37 in human macrophages: a dose finding study for treatment of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Immunostimulants for preventing respiratory tract infection in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Synergistic interactions of TLR2/6 and TLR9 induce a high level of resistance to lung infection in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Toll-like receptor 9 deficiency protects mice against Pseudomonas aeruginosa lung infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3-4 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Reduced use of antimicrobials after vaccination of pigs against porcine proliferative enteropathy in a Danish SPF herd

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Predicting the public health benefit of vaccinating cattle against Escherichia coli O157

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Reverse vaccinology on the cusp

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Identification of enterotoxigenic Escherichia coli (ETEC) clades with long-term global distribution

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Structural vaccinology: a three-dimensional view for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Efficacy of high-dose versus standard-dose influenza vaccine in older adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Designing antimicrobial peptides: form follows function.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Immune modulation by multifaceted cationic host defense (antimicrobial) peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

High expression of a plectasin-derived peptide NZ2114 in Pichia pastoris and its pharmacodynamics, postantibiotic and synergy against Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Perspectives on lantibiotic discovery - where have we failed and what improvements are required?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Azithromycin Synergizes with Cationic Antimicrobial Peptides to Exert Bactericidal and Therapeutic Activity Against Highly Multidrug-Resistant Gram-Negative Bacterial Pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Antimicrobial Peptide Novicidin Synergizes with Rifampin, Ceftriaxone, and Ceftazidime against Antibiotic-Resistant Enterobacteriaceae In Vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Short Proline-Rich Antimicrobial Peptides Inhibit Either the Bacterial 70S Ribosome or the Assembly of its Large 50S Subunit.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

In vivo efficacy and molecular docking of designed peptide that exhibits potent antipneumococcal activity and synergises in combination with penicillin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

An anti-infective peptide that selectively modulates the innate immune response.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Density and duration of pneumococcal carriage is maintained by transforming growth factor β1 and T regulatory cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Therapeutic antimicrobial peptides may compromise natural immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Peptide IDR-1018: modulating the immune system and targeting bacterial biofilms to treat antibiotic-resistant bacterial infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Broad-spectrum anti-biofilm peptide that targets a cellular stress response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Bacterial biofilm development as a multicellular adaptation: antibiotic resistance and new therapeutic strategies.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Preventing acute gut wall damage in infectious diarrhoeas with glycosylated dendrimers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Comparison of the transcriptional landscapes between human and mouse tissues

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

AB103, a CD28 antagonist peptide: a new therapeutic agent in a model of severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Complexities of targeting innate immunity to treat infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Guidelines for the operation of burn centers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Artificial activation of toxin-antitoxin systems as an antibacterial strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

An efficient stress-free strategy to displace stable bacterial plasmids

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Bacteriophage Therapy: Exploiting Smaller Fleas

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Manipulating and understanding antibiotic production in Streptomyces coelicolor A3(2) with decoy oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Oral Administration of β‐Lactamase Preserves Colonization Resistance of Piperacillin‐Treated Mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Orally administered recombinant metallo-beta-lactamase preserves colonization resistance of piperacillin-tazobactam-treated mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Orally administered targeted recombinant Beta-lactamase prevents ampicillin-induced selective pressure on the gut microbiota: a novel approach to reducing antimicrobial resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

P1A recombinant beta-lactamase prevents emergence of antimicrobial resistance in gut microflora of healthy subjects during intravenous administration of ampicillin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Combination therapy with iron chelation and vancomycin in treating murine staphylococcemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Simplified captopril analogues as NDM-1 inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Efficacy of calcium-EDTA as an inhibitor for metallo-β-lactamase in a mouse model of Pseudomonas aeruginosa pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Efficacies of calcium-EDTA in combination with imipenem in a murine model of sepsis caused by Escherichia coli with NDM-1 β-lactamase

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Increased severity of respiratory infections associated with elevated anti-LPS IgG2 which inhibits serum bactericidal killing

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

P4-mediated antibody therapy in an acute model of invasive pneumococcal disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Immunomodulatory adjuvant therapy in severe community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Antimicrobial peptides stage a comeback

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme--New challenges for public health.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

In vivo pharmacodynamic characterization of a novel plectasin antibiotic, NZ2114, in a murine infection model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Plectasin shows intracellular activity against Staphylococcus aureus in human THP-1 monocytes and in a mouse peritonitis model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b:H4-ST131 Escherichia coli strain producing CTX-M-15

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Immunogenicity and pharmacokinetics of short, proline-rich antimicrobial peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

The evolution of the regulatory framework for antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Antibacterial antibodies gain traction

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Trends in risks associated with new drug development: success rates for investigational drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

How to improve R&D productivity: the pharmaceutical industry's grand challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

In Vitro Activity of the Novel Antimicrobial Peptide Dendrimer G3KL against Multidrug-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

Randomized Trial of Rapid Multiplex Polymerase Chain Reaction-Based Blood Culture Identification and Susceptibility Testing.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900466-1

7 January 2021

10.1016/S1473-3099(15)00466-1

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

2628686

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26795692%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

2628686

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

2 references

2628686